Google-backed AI-developed drugs are headed to trial by 2026, says DeepMind CEO

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.